Filing Details
- Accession Number:
- 0001562180-21-007180
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-19 16:06:34
- Reporting Period:
- 2021-11-18
- Accepted Time:
- 2021-11-19 16:06:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1395937 | Syndax Pharmaceuticals Inc | SNDX | Pharmaceutical Preparations (2834) | 320162505 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1597085 | Fabrice Egros | C/O Syndax Pharmaceuticals, Inc. 35 Gatehouse Drive, Building D, Floor 3 Waltham MA 02451 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-11-18 | 14,000 | $8.93 | 30,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-11-18 | 14,000 | $18.03 | 16,000 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-11-18 | 30 | $7.88 | 16,030 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-11-18 | 30 | $18.03 | 16,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (Right to buy) | Disposition | 2021-11-18 | 14,000 | $0.00 | 0 | $8.93 |
Common Stock | Stock Options (Right to buy) | Disposition | 2021-11-18 | 30 | $0.00 | 0 | $7.88 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2028-05-23 | No | 4 | M | Direct | |
0 | 2029-06-10 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
- The sale prices ranged from $18.03 to $19.03.
- This option is fully vested.